drugset / Trial / NCT01776996
An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc
Summary
This is an open-label protocol designed to provide continued access to maraviroc to only those subjects who have completed previous studies of maraviroc and continue to receive clinical benefit.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maraviroc | Other / unclassified | 300 mg | — |
| Background | Lamivudine | Other / unclassified | 150 mg | Oral |
| Background | Zidovudine | Small molecule | 300 mg | Oral |